Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: Results from a cross-sectional survey among staff of a large italian teaching hospital
Articolo
Data di Pubblicazione:
2021
Citazione:
Safety surveillance after BNT162b2 mRNA COVID-19 vaccination: Results from a cross-sectional survey among staff of a large italian teaching hospital / G.P. Vigezzi, A. Lume, M. Minerva, P. Nizzero, A. Biancardi, V. Gianfredi, A. Odone, C. Signorelli, M. Moro. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 92:Suppl. 6(2021 Oct), pp. e2021450.1-e2021450.13. [10.23750/abm.v92iS6.12217]
Abstract:
Background and aim: Comirnaty® was the first COVID-19 vaccine available for the vaccination campaign of healthcare workers in Italy. With the aim of assessing vaccine safety, we conducted a cross-sectional survey administrating a voluntary-based questionnaire on adverse events following immunisation (AEFIs) in San Raffaele Hospital, Milano, Italy. Methods: From 4th January 2021 to 27th April 2021, we collected 2,659 questionnaires (response rate: 24,5%). We analyzed data, reporting AEFIs by gender, age, self-reported severity, type, time of insurgence and duration, and estimating relative-risk ratios (RRR) and corresponding 95% confidence intervals (CI). Results: The most reported symptoms were injection site pain, fatigue, headache, myalgia, chills, fever, and arthralgia. Severe systemic reactions were more frequent after receiving the second dose (RRR 6.25, 95% CI 4.57-8.55), in women (RRR 3.33, 95% CI 2.30-4.82), and less frequent in individuals aged 60 or more (RRR 0.26, 95% CI 0.14-0.49). In addition, we noted a wide range of adverse events of special interest (AESIs). Conclusions: Consistently with clinical trials and pharmacovigilance surveillance, AEFIs were frequent, but severe ones were uncommon, supporting the massive implementation of the COVID-19 vaccination campaign and providing valuable data for a risk profiling of vaccinees. (www. actabiomedica.it).
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Adverse drug reaction reporting systems; COVID-19; Cross-sectional study; Pharmacovigilance; Vaccination; Vaccine
Elenco autori:
G.P. Vigezzi, A. Lume, M. Minerva, P. Nizzero, A. Biancardi, V. Gianfredi, A. Odone, C. Signorelli, M. Moro
Link alla scheda completa:
Link al Full Text: